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We report the development of a heteroduplex-based mutation detection method using multicapillary automated sequencers, known as
conformation-sensitive capillary electrophoresis (CSCE). Our optimized CSCE protocol detected 93 of 95 known base substitution sequence
variants. Since the optimization of the method, we have analyzed 215 Mb of DNA and identified 3397 unique variants. An analysis of this data set
indicates that the sensitivity of CSCE is above 95% in the central 56% of the average PCR product. To fully exploit the mutation detection
capacity of this method, we have developed software, canplot, which automatically compares normal and test results to prioritize samples that are
most likely to contain variants. Using multiple fluorescent dyes, CSCE has the capacity to screen over 2.2 Mb on one ABI3730 each day.
Therefore this technique is suitable for projects where a rapid and sensitive DNA mutation detection system is required.
© 2005 Elsevier Inc. All rights reserved.Keywords: Heteroduplex; Mutation detection; Single-stranded confirmation polymorphism (SSCP); DNA sequencingIntroduction
The reference human genome sequence and genome
sequences of other species provides a resource that has had a
significant impact on the discovery of disease-causing genes.
One of the rate-limiting steps in the gene discovery process is
identification of DNA sequence variants or mutations. Another
is the collection of suitably characterized sets of samples.
Furthermore, following their discovery, many disease genes are
screened in large numbers of susceptible individuals to
determine mutation spectra and prevalence. Screening for
known sequence variants can be performed in many ways;
however, DNA sequencing is the final point in the discovery of
novel variants. Even with recent developments in sequencing
technologies, this can be slow and expensive and the data are⁎ Corresponding author. Fax: +44 1223 494919.
E-mail address: rw1@sanger.ac.uk (R. Wooster).
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doi:10.1016/j.ygeno.2005.11.008complex [1]. An alternative approach is to rapidly screen the
candidate region and then sequence only those areas with
evidence of putative mutations. There is, therefore, a require-
ment for mutation-screening techniques that are rapid, sensitive,
and cost effective.
There are many examples of rapid DNA screening
techniques, such as denaturing gradient gel electrophoresis
[2], chemical cleavage of mismatches [3], single-stranded
confirmation polymorphism [4], the protein truncation test
[5], denaturing high-performance liquid chromatography
(DHPLC) [6], and conformational-sensitive gel electrophoresis
(CSGE) [7]. CSGE is one of the most widely used of these
methods and sensitivity comparisons with other techniques
favored CSGE [8–10]. CSGE has been developed further with
the use of fluorescent labels and slab gel automated sequencers
[11,12] and has been transferred to single-capillary sequencers
[13], where it was named conformation-sensitive capillary
electrophoresis (CSCE). CSCE has been transferred to multiple-
Table 1
Base substitutions in the CSCE optimization set
Substitution Total Detected Missed
C/T G/A 70 68 2
A/C T/G 14 14 0
C/G G/C 4 4 0
T/A A/T 7 7 0
Total 95 93 2
Note. Distribution of single nucleotide variants according to the four nucleotide
substitution classes for the 95 SNPs used in the CSCE optimization set. The
number of SNPs detected and missed by CSCE for each of the substitution types
is shown.
428 H. Davies et al. / Genomics 87 (2006) 427–432capillary sequencers [14–16]; however, these studies analyzed
no more than four genes with at most 120 sequence variants.
Here we report the optimization of CSCE on multicapillary
DNA sequencers together with software to view and prioritize
the traces. In a screen of 215 Mb of DNA for novel sequence
variants, we identified 3397 unique variants, making this the
first demonstration of a truly high-throughput application of
CSCE.
Results
Protocol development and evaluation of mutation detection
sensitivity
A set of 45 PCR products (STSs) containing a total of 95
single-nucleotide polymorphisms (SNPs) were used to establish
the most sensitive conditions for CSCE on both ABI PRISM
3100 and ABI3730 genetic analyzers. The PCR products ranged
in size from 190 to 450 bp and SNPs were located 45 to 174 bp
from the ends of the PCR products. The sequence of the 45
STSs was determined for 24 DNA samples (Coriell Cell
Repositories DNA Polymorphism Discovery Resource Collec-
tion, M24PDR) by DNA sequencing to identify all sequence
variants. These samples were used in the subsequent
optimizations.
The CSCE separation medium was initially optimized for the
ABI3100. A number of variables were assessed in the
optimization. Compared to a 50-cm capillary, a 36-cm capillary
had no significant effect on the separation or resolution of
heteroduplexes but gives shorter run times. Increasing the run
temperature from 18 to 30°C reduced the run time but also
decreased the resolution of heteroduplex peaks, lowering
variant detection efficiency. Increasing the concentration of
CAP polymer from 4 to 7% increased the run time but had no
beneficial effect on heteroduplex resolution or detection. The
inclusion of 2-pyrrolidinone (1–5%), ethanediol (10%), or
glycerol (5%) had no positive effects on heteroduplex
separation or sensitivity. A taurine-based buffer gave a slight
improvement compared to TAPS-based buffer. The inclusion of
urea from 1 to 5.5 M, however, had a dramatic effect on the
separation of heteroduplex peaks. Urea had a beneficial effect
on heteroduplex peak detection in 27% of STSs tested. The
optimum urea concentration was 4 M. Higher concentrations of
urea up to 5.5 M had a detrimental effect on fragment
resolution, particulary on fragments larger than 300 bp.
On the ABI3730, an even spatial calibration across the array
is required to achieve even signal intensities from all 96
capillaries. The ABI3100 protocol produced a very poor spatial
calibration profile on the ABI3730. The refractive index of
POP7, a separation medium recommended for the ABI3730,
was 1.3995, whereas 4 M urea, 5% CAP in 1× TTE (the optimal
ABI3100 mutation detection medium) had a lower refractive
index of 1.3812. Including 5% sucrose increased the refractive
index of the separation medium to 1.3911 and increased the
length of the run time but had no effect on detection sensitivity.
The concentration of sucrose was titered between 5 and 10% to
determine the concentration that would produce an even spatialcalibration profile on the ABI3730 while keeping the run time
to a minimum. The following conditions produced the best
mutation detection sensitivity for ABI3100 and ABI3730: 36-
cm capillaries, 18°C run temperature, 5% CAP polymer, 4 M
urea, 1× TTE, and 7.5% sucrose (ABI3730 only).
Another factor in the optimization of the protocol was the
design of the STSs. The sensitivity of detection in CSGE is
thought to be lower toward the ends of the STS; hence, the 3′
ends of the PCR primers were placed at least 50 bp away from
the sequence to be screened. One STS (stCP250012) was unable
to detect a T to G substitution 48 bp from the end of the
amplimer (the optimal position for the PCR primer dictated a
48-bp extension). The PCR primers were redesigned so the
variant was 77 and 101 bp from the end of the amplimer (STSs
stCP250059 and stCP250060, respectively). In both of the
redesigned assays, the variant was clearly detected. However,
another variant, a G to A, which was undetectable when 50 bp
from the end of the amplimer (stCP250032), remained
undetectable despite redesigning of the PCR primers to position
the variant 95 bp from the end of the amplimer (stCP250062).
STS information is available from http://www.sanger.ac.uk/
genetics/CGP/.
Fragment size is also an important factor in STS design. Five
of the 45 STSs used for the optimization produced fragments
greater than 400 bp. All 10 SNPs present in these five fragments
were detected by CSCE. However, a very subtle shift in a 412-
bp fragment (stCP250043) was more obvious when the primers
were redesigned to reduce the fragment size to 320 bp
(stCP250061). For both the ABI3100 and ABI3730, 93 of the
95 sequence variants were detected in the optimization set,
giving a sensitivity of 98% (Table 1). The two sequence variants
that were not detected were a G to A in a 398-bp amplimer
(stCP250062) and G to A in a 350-bp STS (stCP250031). The
GC content of these fragments was 46.5 and 42.3%,
respectively.
Sequence variant detection in 215 Mb of DNA sequence
Following the optimization, 215 Mb of tumor DNA was
screened for novel sequence variants. Approximately 80% of
the data was generated on the ABI3100, with the remainder
coming from the ABI3730. These data have been combined for
further analysis as both platforms gave identical sensitivities. A
total of 12,687 different STSs were analyzed in one or more
Fig. 1. Estimated probability of mutation detection. Buffers of 22% at each end
of the STS provide an estimated mutation detection rate of at least 95% within
the buffers.
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variants suggested by CSCE identified 4369 true variants, with
1801 sequences being wildtype (giving a false-positive rate of
29.2%). A total of 3397 unique variants were identified in 1711
STSs, giving an average of one variant per 1300 bp of DNA
screened.
In this data set, only those samples with putative mutations
were sequenced. It is possible to compare the general
characteristics of the STSs and the variants that were detected
but not directly compare CSCE and DNA sequencing. The GC
content of the DNA sequence in the STSs that did not yield any
variants (range 20–76%, average 47.40%, SD = 10.90) was
similar to the GC content of STSs in which variants were found
(range 24–71%, average 47.75%, SD = 10.60) and the complete
STS set (range 20–76%, average 47.44%, SD = 10.83). A
subset of 1131 single-basepair substitutions (237 detected on
the ABI3730 and 894 detected on the ABI3100) from 794 STSs
were used for a more in-depth analysis of mutation detection
features of CSCE. In this set, 129 variants were shown to be
somatic mutations by sequencing matched normal DNA,
whereas 1002 were germ-line variants. Of the germ-line
variants, 612 were in the portion of the STSs that covered the
coding sequence. Table 2 is a comparison of the distribution of
the germ-line coding sequence variants detected by CSCE with
the distribution of previously published genome-wide coding
sequence variants.
The heteroduplex method exhibited a greater empirical
sensitivity toward the central portion of the STSs. To estimate
this sensitivity, a probability of mutation detection was
calculated as a function of the percentage distance of a
mutation from the nearest end of the STS in question. This
was modeled as a cumulative beta distribution (see Materials
and methods). A buffer at each end of the STS can then be
designed to ensure the greatest sensitivity across the region of
interest. As seen in Fig. 1, designing buffers of 22% at each
end resulted in an estimated detection rate in excess of 95%
between the buffers.
CSCE trace analysis
The CSCE method has the ability to produce approximately
10,000 traces per ABI3730 per day. To prioritize traces for
further analysis, a trace comparison program, canplot, was
developed to identify samples with putative sequence variantsTable 2
Comparison of single nucleotide variants in the coding regions of the human
genome and germ-line coding variants detected by CSCE
Substitution Variants in the coding genome (%) Variants found by CSCE (%)
C/T G/A 42,448 (70.1) 442 (72.2)
A/C T/G 9188 (15.2) 104 (17.0)
C/G G/C 6292 (10.4) 47 (7.7)
T/A A/T 2660 (4.4) 19 (3.1)
Note. The distribution of single nucleotide variants in the four nucleotide
substitution classes for the coding region of the human genome as a whole (from
Ensembl, http://www.ensembl.org) and those germ-line coding variants detected
using CSCE.by comparing traces from a reference and test sample.
Furthermore, canplot interacted with our laboratory information
management system to enable the seamless tracking of data. A
visual examination of the trace data from the initial optimization
experiments suggested that samples with the same sequence had
very similar trace profiles, whereas those with a sequence
variant had either additional peaks or one or more shoulders on
the primary peak. Canplot used two tests, the presence of
additional peaks above the background and the presence of
shoulders in the primary peak, to prioritize traces for visual
inspection. Ultimately all traces were examined to minimize the
loss of data. Canplot also aided in the inspection of the data by
clipping the trace to present only the region with the
heteroduplex peaks and rescaling the control and test peaks to
simplify visual comparison (Fig. 2). In an analysis of 808,618
tumor traces, canplot suggested that 159,062 (20%) were likely
to contain sequence variants. After human review, 31,985 of
these traces were considered sufficiently different to warrant
sequencing. Human review identified a further 7028 traces for
sequencing in the 649,556 traces that canplot called normal.
Therefore, this set of 808,618 CSCE experiments led to 39,013
sequencing experiments, representing a 95% reduction in the
sequencing load. Canplot successfully prioritized 80% of the
trace data containing 82% of the samples that were sent for
sequencing.
Discussion
The reference human genome sequence and its annotation
provide many more candidate genes and other sequence features
than ever before for the study of genetic diseases. Screening
candidate sequences for novel variants and mutations requires
methods that are fast, sensitive, specific, and economical. There
are a number of emerging sequencing technologies that may
satisfy all of these criteria at some point in the future [17]. In the
meantime, Sanger dideoxysequencing is the final step in
determining novel variants. An alternative strategy is to adopt
a rapid screening approach followed by direct sequencing of
Fig. 2. CSCE traces as presented by canplot software. The control trace is shown in black and the test trace in green. The scale on the left-hand side indicates the
intensity of the control trace and the test is on the right-hand side. (a) Example of an A to G substitution 126 bp from the end of a 331-bp fragment analyzed on an
ABI3100. This fragment resolves into four peaks representing both homoduplexes and both species of heteroduplex. (b) The same 331-bp fragment analyzed on an
ABI3730. (c) A 265-bp STS with a C to T substitution 86 bp from the end. (d) The same 265-bp fragment as in (c) analyzed on an ABI3730.
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one of the most widely used rapid screening methods.
The initial optimization of the sensitivity of this protocol was
performed using a direct comparison to DNA sequencing. This
is in contrast to other reports that compare capillary heterodu-
plex methods with results obtained from other prescreening
techniques such as CSGE [15]. The optimized protocol detected
93 of the 95 SNPs in the original test set. There were no obvious
explanations for the 2 SNPs that were not detected in terms of
SNP position, STS length, or GC content. Previous experience
indicated that insertions and deletions from 1 to 25 bp always
resulted in additional peaks in heteroduplex analysis. Therefore,
these were not considered during optimization.
It was determined that 48.4% of the 215 Mb of tumor DNA
screened was coding sequence. The distribution of single-
nucleotide variants discovered in this set matches the known
distribution of variants across the whole coding human genome
(Table 2). This suggests that there were no major biases in the
detection ability of CSCE. Mutation detection sensitivity by
heteroduplex methods is thought to decrease in the last 50 bp of
the fragment [7] and was the basis of our original design
parameters. However, the analysis of the variants detected in the
215 Mb of sequence indicates that the buffer size should be
larger, with 95% of variants detected with a 22% buffer, i.e., an
88-bp buffer for a 400-bp amplimer. Previous data suggested
that very high or low GC content reduces the sensitivity of
heteroduplex methods [7]. CSCE detected sequence variants inSTSs with GC content ranging from 24 to 71%. This suggests
that the GC content of the human coding sequence (as
determined by cDNA GC content of 30 to 70% with maxima
at 42 and 58% [18]) will not hinder CSCE.
CSCE analysis has a specificity of 70.8% where 4369 of
6170 putative variants were confirmed by DNA sequencing.
This is a conservative value, as the objective was to find as
many variants as possible and hence sequence weak candidates
as well as those with a high probability of being mutant. Unlike
some methods, for example, DHPLC [6], CSCE does not
require either a precalculation of run conditions or an empirical
determination using known variants. Hence, a single set of run
parameters is used for all fragments. Based on 400-bp fragments
and buffers of 22% at each end for maximum mutation
detection, up to 2.2 Mb can be screened per day on an ABI3730
or 649 kb per day on an ABI3100. One ABI3730 has the
potential to create over 10,000 trace files per day. Canplot was
written to identify those samples that are most likely to contain
variants. This increased the throughput of CSCE analysis and
assisted in the prioritization of experiments.
The discovery of novel DNA variants is continuing to play
an important role in our understanding of human disease. CSCE
is a sensitive method that allows the swift identification of
variant genes in disease, for example, BRAF in cancer [19].
Until it is possible to completely resequence whole genomes, it
is likely that CSCE coupled with DNA sequencing will continue
to expedite these discoveries.
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PCR
Primers were designed to amplify the coding exons of interest plus 50 bp of
intronic sequence at either end of the exon. The maximum PCR fragment size
was 400 bp with overlapping STSs for larger exons (minimum of 100-bp
overlap). One of the primers in each pair was labeled with FAM, VIC, or NED
fluorescent dye (Applied Biosystems). Primer sequences for the initial
optimization set of 45 STSs are available from http://www.sanger.ac.uk/
genetics/CGP/.
Fifteen-microliter PCRs were performed using the following: 20 ng each
primer, 100 μM each dNTP, 10 mM Tris–HCl, pH 8.3, 50 mM KCl, 1.5 mM
MgCl2, 0.001% gelatin, 0.3 units Abgene Thermostart Taq, 12 ng test DNA, 3
ng control DNA. PCR was carried out in a DT-108 Super Duncan water bath
thermocycler (KBiosystems) as follows: 95°C for 15 min, 40 cycles of 95°C for
30 s, 60°C for 30 s, 72°C for 30 s, followed by a final extension at 72°C for 10
min. An additional denaturation step followed by slow cooling was used to
maximize the formation of heteroduplexes. This involved heating to 96°C for 10
min followed by a slow cooling of 1.5°C per minute to 60°C; samples were held
at 60°C for a further 30 min.
Capillary electrophoresis
PCR fragments were diluted in 1× PCR buffer in the range of 0 to 1/10 (the
dilution was STS specific and was determined by testing two samples). The
diluted fragments were pooled (one each of FAM, VIC, and NED) and diluted 1/
30 in water to give a final dilution in the range 1/30 to 1/300 of the primary PCR.
Prior to loading on the ABI3100 or ABI3730, 2.5 μl of the pooled and diluted
PCR product was added to 7.5 μl of water and 0.1 μl GeneScan 500 LIZ size
standard (Applied Biosystems Catalogue No. 4322682).
For the ABI3100, the run conditions were as follows: 16 capillaries, 36-cm
array, and standard GeneScan36_POP4 module with modifications including a
run temperature of 18°C, a run time of 900 s, sample injection of 15 kV for 5 s,
dye set G5. The separation medium used contains 5% CAP polymer (Applied
Biosystems Catalogue No. 4340379), 4 M urea, 1× TTE (90 mM Tris, pH 9.0,
8.5 mM taurine, 0.5 mM EDTA, National Diagnostics EC-871). For the
ABI3730, the run conditions were as follows: 36-cm 96-capillary array and
standard GeneScan36_POP7 module with modifications including a run
temperature of 18°C, a run time of 720 s, a data delay time of 750 s, sample
injection of 15 kV for 10 s, dye set G5. The separation medium was 5% CAP
polymer, 4 M urea, 7.5% sucrose, 1× TTE. The running buffer for both methods
is 1× TTE and both separation media are stable for at least 2 weeks at 4°C. Data
collection software for the ABI3100 and ABI3730 was 3100 Data Collection
Software Version 1.0.1 and 3730XL DNA Analyser Data Collection Software
Version 1.0, respectively.
Refractive indexes were measured on an Abbe 60 refractometer according to
the manufacturer’s instructions.
Trace analysis
The trace files from the ABI3100 or ABI3730 were analyzed using
proprietary software written in IDL (available from the authors upon request).
The sensitivity and specificity parameters for canplot were optimized using
the initial set of 45 STSs. Prior to any manipulation, all data channels were
smoothed using a 5-point smoothing process. The LIZ-labeled size standard
was used to perform a conversion of the x-axis scan index (which is time-
like) to fragment size in basepairs using a cubic spline interpolation, followed
by a linear re-interpolation onto a regular fragment-size axis scale. Next, all
peaks within a data channel were located using a peak model that stipulated
that the peak maximum must have positive gradients on the left-hand side
and negative gradients on the right-hand side. The peak with maximum
intensity was used to define a primary peak, whereas secondary peaks within
400 scan indices of the primary peak were also assigned to the marker-
specific signal. The peak-finding process was applied to tumor and normal
traces and the two were scaled to one another using the intensities of the
primary peaks. If the number of clearly resolved peaks present in the normaland tumor traces were different, the tumor was prioritized for review. If the
numbers of peaks were identical, a peak shoulder comparison algorithm was
used to assess the symmetry characteristics of the tumor and normal signals.
If the extent of any shoulder mismatch was greater than a critical width of
0.5 bp, the trace was prioritized for review. All other traces were given a low
priority for review.
DNA sequencing
Samples with putative mutations were re-amplified using unlabeled PCR
primers of the same sequence as the original CSCE primers. The PCR products
were sequenced using a BigDye Terminator Cycle Sequencing Ready Reaction
Kit (Applied Biosystems) according to the manufacturer’s protocol and
analyzed on an ABI3100 or ABI3730.
Statistical methods
To quantify the observed decline of the heteroduplex method’s ability to
detect mutations toward the ends of STSs, a model was fitted as described below.
x denotes the percentage distance of a mutation to the nearest end of the STS
containing the mutation. D denotes the event that the mutation is detected. p
(D∣x) denotes the probability that the heteroduplex method will detect the
mutation, given position x. It is assumed that this probability takes the form of a
(rescaled) cumulative distribution of a beta random variable,
p Djxð Þ ¼
Z x=50
0
Cðaþ bÞ
CðaÞCðbÞ z
a1ð1 zÞb1dz:
This is a two-parameter distribution, the values α and β of which are fitted
from the observed mutation positions. These observations derive from the
distribution of mutations, given detection, p(D∣x). These two distributions are
connected via Bayes law, where
pðxjDÞ~pðDjxÞpðxÞ:
Assuming the distribution of mutations p(x) is uniform gives, upon
normalization,
p xjDð Þ ¼ pðDjxÞR 50
0 pðDjxÞdx
:
The parameters α and β can then be estimated from the data by standard
fitting methods. The method of moments was used to fit the curve in Fig. 1,
based on 1131 observed mutations.Acknowledgment
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